**Description**

**A FORMULATION DEVELOPED FOR TREATMENT OF SUBSTANCE ADDICTION**

**Field of Invention**

The present invention herewith is related to a formulation developed for treatment of substance addiction.

**Background of the Related Technology**

At present substance addiction is defined as the insuppressible need of a body to use certain substances like alcohol, cigarettes and narcotics, a need that has developed upon using such substances. People using narcotics can be treated. Substance use and addiction is a health problem and its treatment is possible. The rate of quitting narcotics is especially very high among people who abide with the principles of related treatment. There is a general misconception among the users that “such an addiction cannot be treated.” Effort must be put to change this misconception. Among people who stop using narcotics, restarting is a situation that is frequently observed. A person who stops using narcotics should refrain from using them again in any way. Even using it once can lead for him/her to start the abuse all over again.

Based on the information related to the technology, once a person applies for treatment, first the body needs to be cleared off from the related substances, and this process is called detoxification. It might be dangerous for oneself to suddenly stop using certain materials like heroin, without any support. Thus, the person should stop using them under control. Then, support will be given to the person for him/her to understand himself/herself, to learn his/her behavior in using the substance, to understand why he/she used it and what he/she should do to ensure that he/she does not start using it again. The first step in addiction treatment is always medical detoxification. Detoxification treatment is treatment of symptoms observed when the body is detoxified from the related substance, using certain drugs. Detoxification alone is observed not to be sufficient in treatment of substance addiction, however it is the first step in a long term addiction treatment.

The invention presented herewith with no “EP1397138B1", with title " A Combination of Active Materials (drugs like galanthamine or desoxy-peganine as well as drugs like acamprosate or memantine) Against Narcotics or Addictive Substances” and under classification number “A61K 31/505", is related to a combination of at least one modulator of the cholinergic system used in treatment of substance addiction like alcoholism with drugs and at least one agent that has a sedating effect.

Again the invention presented herewith with no “EP1383503B1", with title "Using Desoxy-Peganine in Treatment of Central Nervous System Symptoms Caused by Toxification through Psychotropes” and under classification number “A61K 31/505", is related to using desoxy-peganine as free base or acid additive salt for production of medical drugs with the purpose of treating withdrawal signs developing in the brain or central nervous system based on narcotic addiction or chronic alcohol addiction, specifically the repetitive withdrawal symptoms, and treating cerebral, central nervous system or psychiatric symptoms that has developed in humans or other vertebrates as a chronic result of diseases or pyschotropes.

Again the invention presented herewith with no “EP2089030B1", with title "An Agent for Treatment or Prophylaxis of Alcohol Addiction or Drug Addiction” and under classification number “A61K 31/454", is related to providing and agent that contains a compound with formula (1) that is represented with (R)-2-{3-[1- acenaphthene -1-yl)piperidine-4-yl]-2,3-dihydro-2-oxo-benzimidazole-1-yl}-N-methylacetamide as an active ingredient for treatment or prophylaxis of substance abuse and addiction or a pharmaceutically acceptable salt of the compound thereof.

Again the invention presented herewith with no “PCT/CN2011/000900", with title "A Pharmaceutic Composition for Treatment of Drug Addiction " and under classification number “A61K 36/81", is related to a pharmaceutic composition for treatment of narcotic addiction, which consists of Gelsemium elegans Benth. herbal plant and Datura metel L. herbal plant flower and optionally any pharmaceutically acceptable additive and where the weight to weight ratio of Gelsemium elegans Benth. Raw material to Datura metel L. flower raw material is between 2:1 and 6:1.

Again the invention presented herewith with no “EP1868600B1", with title "Spirocyclic Cyclohexane Derivatives Intended for Treatment of Substance Addiction” and under classification number “A61K 31/407", is related to using spirocyclic cyclohexane derivatives for production of a drug intended to be used in treatment of substance addiction.

Again the invention presented herewith with no “EP1767221B1", with title "Preparing and Using Double Vaccine Against Morphine-Heroin Addiction” and under classification number “A61K 47/48", is related with a method for preparation of a double immunogenic composition against morphine-heroin addiction and includes a reaction between a carrier protein (“CP”) and a morphine type product. The carrier protein is tetanus toxoid and the morphine type product is EDC-(morphine-6-hemi succinate). This morphine type product binds to the intermediate material conjugate ("CP-TFCS") in the composition.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a composition developed for treatment of substance addiction.

**Objective of the Invention**

To overcome the disadvantages referred in the Background of the Related Technology,

* One objective of the present invention is, suppression of secretion of catecholamine from adrenal chromaffin cells;
* One other objective of the invention is to enhance production of adrenal androgens;
* One other objective of the invention is to increase acetylcholine secretion;
* One other objective of the invention is enhance beta-endorphine production;
* One other objective of the invention is to enhance serotonin production;
* One other objective of the invention is to enhance production of endogenous cannabinoid derivatives.

The present invention which is aimed to achieve the above-mentioned advantages, is intended for treatment of substance addiction and is a composition that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one,  2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention is related to a formulation developed for treatment of substance addiction. The referred formulation, suppresses secretion of catecholamine from adrenal chromaffin cells, enhances production of adrenal androgens, increases acetylcholine secretion, enhances beta-endorphine production, enhances serotonin production, enhance production of endogenous cannabinoid derivatives.

Formulation related to the present invention contains; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one,  2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one.

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 3-10% of 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one,
* 17-20% of 2,3-bis(6-oxoethyl)-4-0-dioxin,
* 20-10% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one,
* 40-20% of 11-oxo-alphamethyldioxin,
* 20-40% of 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time is related to using the above-referred composition for treatment of substance addiction and manufacturing it for such purpose.

**CLAIMS**

1. A composition intended for treatment of substance addiction, which consists of combining the components selected from the group; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one,  2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-onen a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing 3-10% of 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one by weight.
3. The formulation of Claim 1 which is characterized by containing 17-20% of 2,3-bis(6-oxoethyl)-4-0-dioxin by weight.
4. The formulation of Claim 1 which is characterized by containing 20-10% of 3,5-methoxy-stigmast-6-ene-phenyl-4-one by weight.
5. The formulation of Claim 1 which is characterized by containing 40-20% of 11-oxo-alphamethyldioxin by weight.
6. The formulation of Claim 1 which is characterized by containing 20-40% of 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one by weight.
7. Using the compositions obtained by selecting singly or in combination of components from the group of; 16,20-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one,  2,3-bis(6-oxoethyl)-4-0-dioxin, 3,5-methoxy-stigmast-6-ene-phenyl-4-one, 11-oxo-alphamethyldioxin, 3,5-bis(2-dimethyl)-6-O-stigmast-4-ene-coumaroil-3-one from any one as given in Claims 2-6 in manufacturing the composition intended for treatment of substance addiction.

**SUMMARY**

**A FORMULATION DEVELOPED FOR TREATMENT OF SUBSTANCE ADDICTION**

The present invention is related to a formulation developed for treatment of substance addiction. The referred formulation, suppresses secretion of catecholamine from adrenal chromaffin cells, enhances production of adrenal androgens, increases acetylcholine secretion, enhances beta-endorphine production, enhances serotonin production, enhance production of endogenous cannabinoid derivatives..

There are no illustrations.